# InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Submits Protocol for Phase II Concussion Trial in New Zealand

Oragenics (NYSE American: OGEN) announced the submission of its Phase II clinical trial protocol to New Zealand’s Health and Disability Ethics Committee, advancing plans to evaluate ONP-002, its intranasal neurosteroid therapy for mild traumatic brain injury. If approved, patient enrollment will begin at Christchurch Hospital, one of Australasia’s busiest emergency care centers. The company aims to expand its clinical reach across Australia and New Zealand, addressing a major unmet need for concussion treatment.

 To view the full press release, visit https://ibn.fm/PCM72

 About Oragenics

 Oragenics is a development-stage biotechnology company focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (“mTBI”), also known as concussion, and for treating Niemann Pick Disease Type C (“NPC”), as well as proprietary powder formulation and an intranasal delivery device. For more information, visit the company’s website at www.Oragenics.com

 NOTE TO INVESTORS: The latest news and updates relating to OGEN are available in the company’s newsroom at https://ibn.fm/OGEN

 About InvestorWire

 InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

 For more information, please visit https://www.InvestorWire.com

 Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

 InvestorWireAustin, Texaswww.InvestorWire.com512.354.7000 OfficeEditor@InvestorWire.com

 InvestorWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/iw/investornewsbreaks-oragenics-inc-nyse-american-ogen-submits-protocol-for-phase-ii-concussion-trial-in-new-zealand/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/oragenics-advances-clinical-trial-for-concussion-treatment-in-new-zealand/49e64f58201dac8363f832ede8782cd7) 

 



[Reddit Post](https://www.reddit.com/r/HealthCareNewsInfo/comments/1k02yko/oragenics_advances_clinical_trial_for_concussion/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/254/15/taroSXrz.webp)